Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: August 27, 2021
Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials.
Journal: Journal of Parkinson's disease
Published: May 14, 2019
Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials.
Journal: Parkinsonism & related disorders
Published: June 05, 2018
Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia.
Journal: Clinical pharmacokinetics
Published: May 20, 2018
Author Correction to: Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.
Journal: CNS drugs
Published: April 11, 2018
Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: January 26, 2018
Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102.
Journal: Movement disorders clinical practice
Published: October 18, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026